- About
- PsychU For You
- Topics
- Events
- Content
Pathophysiology Of Agitation Associated With Alzheimer’s Dementia: The Potential Role Of The Norepinephrine, Serotonin, & Dopamine (NSD) Neurotransmitter Systems
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Pathophysiology Of Agitation Associated With Alzheimer’s Dementia: The Potential Role Of The Norepinephrine, Serotonin, & Dopamine (NSD) Neurotransmitter Systems
Tau pathology and neurodegeneration in key prefrontal and subcortical brain regions may increase the risk of developing agitation in Alzheimer’s dementia.1 Specifically, agitation in Alzheimer’s dementia may reflect an imbalance between top-down executive control (i.e., hypoactivity in prefrontal regions) and bottom-up emotional drive (i.e., hyperactivity in subcortical regions including the amygdala).1 Moreover, agitation in Alzheimer’s dementia is associated with noradrenergic, serotonergic, and dopaminergic system dysfunction in brain circuits mediating the balance between executive control and emotional drive.2,3 In this webinar, the speakers will review the loss of behavior regulation and the role of the monoamine system in the pathophysiology of agitation associated with Alzheimer’s Dementia.
References
- Rosenberg, P.B., et al. Mol Aspects Med. 2015; 43-44: 25-37.
- Jacobs, H.I., et al. Mol Psychiatry. 2021; 26(3): 897-906.
- 3. Lanctôt, K.L., et al. J Neuropsychiatry Clin Neurosci. 2001; 13(1): 5-21.
Laura Brennan, PhD (OPDC)
Medical Science Liaison
Miranda Fisher, PhD (OPDC)
Medical Science Liaison
Speakers Laura Brennan, PhD and Miranda Fisher, PhD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
If you enjoyed today’s webinar, please be sure to check out our upcoming webinar, “Burden & Treatment Considerations For Agitation Associated With Alzheimer’s Dementia“.
Registration
- PsychU For You
